Financials
2nd Quarter Results | Jul. 31, 2024 |
1st Quarter Results | May. 01, 2024 |
GSK Annual Report 2023 on Form 20-F | Mar. 05, 2024 |
GSK publishes Annual Report 2023 | Mar. 01, 2024 |
Final Results | Jan. 31, 2024 |
3rd Quarter Results | Nov. 01, 2023 |
2nd Quarter Results | Jul. 26, 2023 |
Proxies
Result of AGM | May. 08, 2024 |
GSK Proxy Form 2024 | Mar. 25, 2024 |
GSK AGM Notice 2024 | Mar. 25, 2024 |
Notice of AGM | Mar. 25, 2024 |
GSK Proxy Form 2023 | Mar. 27, 2023 |
GSK AGM Notice 2023 | Mar. 27, 2023 |
Publication of 2023 AGM Notice | Mar. 27, 2023 |
Ownership Update
Director/PDMR Shareholding | Sep. 06, 2024 |
Director/PDMR Shareholding | Aug. 21, 2024 |
Director/PDMR Shareholding | Aug. 20, 2024 |
Director/PDMR Shareholding | Aug. 12, 2024 |
Director/PDMR Shareholding | Jul. 18, 2024 |
Director/PDMR Shareholding | Jul. 16, 2024 |
Director/PDMR Shareholding | Jul. 15, 2024 |
Announcements
Positive Phase III results for Nucala in COPD | Sep. 06, 2024 |
Total Voting Rights | Sep. 02, 2024 |
EMA approval on Arexvy for 50-59 at risk | Aug. 29, 2024 |
SENKU Designation for Bepirovirsen in Japan | Aug. 28, 2024 |
Nucala approved in Japan for use in CRSwNP | Aug. 28, 2024 |
Statement: Zantac (ranitidine) litigation | Aug. 28, 2024 |
B7-H3 ADC US FDA Breakthrough Therapy Designation | Aug. 20, 2024 |
Prospectuses
GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |